Uso continuado de inhibidores de la PDE5 en el tratamiento de la disfunción eréctil: nuevas perspectivas y oportunidades

Puigvert, Ana María; Prieto, Rafael; García, Ferrán.
Rev. int. androl. (Internet) ; 16(1): 28-33, ene.-mar. 2018. tab
Artículo en Español | IBECS (España) | ID: ibc-170577

Documentos relacionados

  1. The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.
  2. Breast Cancer Resistance Protein Limits Fetal Transfer of Tadalafil in Mice.
  3. Oral drugs used to treat persistent pulmonary hypertension of the newborn.
  4. Bioequivalence of 2 Formulations of Sildenafil Oral Soluble Film 100 mg and Sildenafil Citrate (Viagra) 100 mg Oral Tablets in Healthy Male Volunteers.
  5. Intra-amniotic sildenafil administration in rabbits: Safety, pharmacokinetics, organ distribution and histologic evaluation.
  6. Uso de tadalafilo en la rehabilitación de pacientes con antecedente de lesión de uretra posterior en el contexto de fractura pélvica
  7. A UPLC-MS/MS method for simultaneous quantification of sildenafil and N-desmethyl sildenafil applied in pharmacokinetic and bioequivalence studies in a Chinese population.
  8. [Pharmacokinetic features of sildenafil spray in healthy men depending on food intake].
  9. The influence of Eruca sativa (Arugula) on pharmacokinetics of Sildenafil in rats.
  10. Pharmacokinetic modeling of intravenous sildenafil in newborns with congenital diaphragmatic hernia.